The M&A wave is no longer just a big pharma story. Monday brought two more deals, but neither came from the usual mega cap buyers. Ipsen, the French mid cap, paid $450 million upfront (up to $1.75 billion with milestones) for Kartos Therapeutics and its Phase 3 myelofibrosis drug. Zymeworks, a Canadian biotech better known as a licensor than an acquirer, spent close to $1 billion to buy Theravance Biopharma for a lung disease drug and a set of royalty streams. Two deals, two buyers that do not show up on the usual “who is hunting” lists, both on the same Monday.
That breadth tells you something. When mid caps and biotechs start acquiring alongside the Lillys and AbbVies, the dealmaking is structural, not cyclical. The patent cliff that H.C. Wainwright pegs at $236 billion to $300 billion through 2030, with nearly 70 blockbusters losing protection, is forcing the entire industry to restock—not just the top tier. Total first half M&A exceeds $134 billion across 33 deals over $1 billion. The second half starts tomorrow. And so does the Medicare GLP 1 Bridge. But first, the FDA threw Capricor a curveball, setting a surprise advisory committee meeting for a Duchenne therapy it already rejected once, complicating the “agency is easing up” narrative we described yesterday.
Ipsen Acquires Kartos for Up to $1.75B in Myelofibrosis
What Happened: Ipsen agreed to acquire Kartos Therapeutics for $450 million upfront with total deal value reaching as much as $1.75 billion if milestones are met. The prize is navtemadlin, a Phase 3 MDM2 inhibitor designed to improve outcomes for patients on ruxolitinib (Jakafi), the standard of care for myelofibrosis.
Why This Deal Matters for the M&A Story
BioSpace framed the acquisition as Ipsen making “multiple shots around a core franchise, not one binary replacement bet.” That framing captures a strategic shift happening across mid cap pharma. Rather than betting the company on a single transformative acquisition (the way AbbVie bet $10.9 billion on Apogee or GSK bet $10.6 billion on Nuvalent), mid caps are assembling portfolios of mid sized assets around their existing therapeutic strengths. The approach lowers binary risk and is more financeable for companies without the balance sheet capacity of a top ten pharma.
For the myelofibrosis landscape specifically, navtemadlin joins Lilly’s Ajax Therapeutics Type II JAK2 inhibitor (which showed early clinical activity “working right out of the gate” on June 13) as another asset targeting the ruxolitinib resistance population. Patients who progress on Jakafi—the standard of care since 2011—have limited options. Both navtemadlin (MDM2 inhibition alongside Jakafi) and Lilly’s AJ1 11095 (Type II JAK2 binding) address this unmet need through different mechanisms. The competition to serve the post Jakafi population is intensifying.
What Ipsen Is Building
Ipsen is a focused mid cap with existing franchises in oncology and rare disease. The Kartos acquisition deepens the oncology pipeline without requiring the kind of organizational transformation that a diversifying deal would demand. The company knows how to develop and sell oncology drugs to hematologists and oncologists. Navtemadlin fits that infrastructure. The milestone heavy deal structure ($450 million upfront, up to $1.3 billion in additional milestones) means most of the economic commitment is tied to clinical and regulatory success, reducing Ipsen’s financial risk if the program does not advance as expected.
Zymeworks Acquires Theravance for Close to $1B
What Happened: Zymeworks agreed to acquire Theravance Biopharma in a deal worth close to $1 billion, gaining a lung disease drug and a portfolio of royalty streams. Theravance shares dipped 2.7% to $17.15.
A Biotech Becoming an Acquirer
For Zymeworks, historically known for its antibody engineering platform and licensing deals (the company has licensed its bispecific antibody technology to multiple pharma partners), buying a commercial stage asset and royalty income is a notable strategic shift. The company is moving from a platform licensing model—where it earns milestones and royalties by out licensing technology to partners—toward becoming a more diversified, revenue generating company with its own products and income streams.
The lung disease drug gives Zymeworks a clinical or commercial stage asset in respiratory medicine, a therapeutic area where the company has not previously operated. The royalty streams provide near term revenue that reduces cash burn and extends the company’s financial runway. For a biotech making the transition from platform licensor to integrated pharmaceutical company, the combination of a product asset and royalty income is a pragmatic foundation.
The Theravance shares dipping 2.7% on the announcement suggests the market viewed the deal price as fair to slightly disappointing for Theravance shareholders—not a premium rich transaction, but one that provides certainty and liquidity for a company whose standalone path may have been more uncertain.
FDA Sets Surprise Advisory Committee for Capricor’s Duchenne Therapy
What Happened: The FDA will hold an advisory committee meeting to discuss Capricor Therapeutics’ deramiocel for Duchenne muscular dystrophy cardiomyopathy. The drug was rejected last July. CEO Linda Marbán told BioSpace the news surprised her because the FDA had not communicated any concerns about the resubmitted application.
The Uneven FDA Reset
Yesterday we wrote that the FDA’s regulatory posture appears to be shifting under acting leadership, pointing to the Replimune RP1 acceptance after two CRLs, the UniQure Huntington’s reversal, and the REGENXBIO Duchenne filing. Today’s Capricor news is the counterweight.
An advisory committee meeting is generally a signal that FDA reviewers want external input before making a decision on a borderline application. The agency is not rejecting deramiocel—it is adding a procedural step. But that step introduces uncertainty that the company did not expect. Marbán saying the FDA had not flagged any concerns makes the adcomm a genuine surprise, not a routine part of the review process.
The August 22 PDUFA date we have tracked in our catalyst calendar is now uncertain. Advisory committees typically occur four to six weeks before the PDUFA date, meaning the timeline may shift. For Duchenne patients with cardiomyopathy—the cardiac complications that are a leading cause of death in Duchenne—the delay adds time to an already long wait for a targeted treatment.
The lesson for the industry: the FDA under acting leadership is not uniformly more permissive or more restrictive. It is uneven. The same agency can ease up on one rare disease filing and add scrutiny to another in the same week. Some reviewers are taking a more constructive stance. Others are following standard procedural caution. Without a permanent commissioner setting a consistent regulatory philosophy, expect this inconsistency to continue. Companies should build advisory committee risk into every rare disease filing timeline rather than assuming the more favorable pattern applies to their program specifically.
Viridian’s Lumvoa Approved for Thyroid Eye Disease
What Happened: The FDA approved Viridian Therapeutics’ Lumvoa (veligrotug) for thyroid eye disease on Friday, sending shares up more than 10% to $19.81. Lumvoa is an anti IGF 1R antibody that competes directly with Amgen’s Tepezza.
A New Challenger in a One Drug Market
Tepezza has owned the thyroid eye disease market since its 2020 launch. It was the first approved targeted therapy for TED, a condition where antibodies cause inflammation and swelling behind the eyes, leading to bulging, double vision, and in severe cases, vision loss. Tepezza generates significant revenue for Amgen and has had no approved targeted competitor until now.
Lumvoa enters with a shorter infusion course, which is a meaningful convenience advantage in a disease where patients are dealing with active, often disfiguring symptoms and want resolution as quickly as possible. The competitive dynamic mirrors what we are seeing across therapeutic areas: a dominant first mover facing a next generation challenger that competes on convenience and patient experience as much as on raw efficacy. AbbVie’s $10.9 billion bet on zumilokibart (two to four injections per year versus Dupixent’s 26) follows the same logic. When two drugs offer comparable clinical outcomes, the one that is easier to take wins.
For Viridian, which is also developing a subcutaneous formulation for TED, the Lumvoa approval is the first step in building a franchise that could eventually offer both infusion and self injection options. For Amgen, the loss of TED market exclusivity comes at a time when the company is also navigating the Tavneos regulatory challenges (FDA voluntary removal request, CHMP revocation recommendation).
Enhertu Receives EU Tumor Agnostic Approval
What Happened: The European Commission approved AstraZeneca and Daiichi Sankyo’s Enhertu as a monotherapy for adults with HER2 positive (IHC 3+) solid tumors who have exhausted other options.
Why This Matters: This is a tumor agnostic approval, meaning Enhertu can now be prescribed in Europe based on the presence of HER2 overexpression regardless of where in the body the cancer originated. The approval extends the ADC’s reach beyond its existing breast cancer, lung cancer, and gastric cancer indications to any solid tumor that tests HER2 positive at the highest expression level. Tumor agnostic approvals represent the frontier of precision oncology: treating cancer by its molecular characteristics rather than its anatomical location.
For Daiichi Sankyo’s $14.6 billion oncology revenue target by 2030, tumor agnostic approvals are essential. Each new indication adds a patient population. A tumor agnostic label encompasses patients across dozens of cancer types who would not be eligible under tumor specific approvals. This is the ADC franchise expanding at the molecular level rather than one indication at a time.
Medicare GLP 1 Bridge Launches Tomorrow
The program goes live Wednesday July 1. For the first time, Medicare Part D beneficiaries will have access to GLP 1 obesity and diabetes therapies at a $50 per month copay. Both Lilly products (Foundayo for oral convenience, Zepbound for injectable efficacy) and both Novo products (oral Wegovy, injectable Wegovy) are covered.
This is the most significant expansion of obesity treatment access in Medicare’s history. For approximately 65 million Medicare beneficiaries, GLP 1 therapy has been largely out of reach—list prices of $500 to $1,000 per month made these drugs unaffordable for most seniors on fixed incomes. Tomorrow that changes. The first enrollment numbers, expected within days of launch, will tell us more about real world demand for GLP 1 therapy in the senior population than any analyst model or survey has been able to predict. The data will be watched by investors, policymakers, insurance actuaries, and every company with a stake in the obesity and diabetes market.
Strategic Themes
1. Mid Cap and Biotech Buyers Entering the M&A Market Is the Strongest Signal That the Cycle Is Structural
When only Lilly, AbbVie, and GSK are buying, you can call it big pharma strategy. When Ipsen, Zymeworks, Biogen, Servier, Chiesi, UCB, and LEO Pharma are all buying in the same six month period, you have a structural industry realignment. The patent cliff does not discriminate by company size. Every pharmaceutical company with a franchise to defend needs pipeline assets. The $236 billion to $300 billion in revenue exposure through 2030 affects mid caps and biotechs just as urgently as it affects the mega caps. The broadening of the buyer base is the strongest evidence that the M&A cycle will continue into the second half and beyond.
2. The FDA Under Acting Leadership Is Real but Uneven
Replimune accepted after two CRLs. UniQure reversed. REGENXBIO on track. Capricor gets a surprise adcomm. The pattern is not that the FDA is uniformly more permissive. The pattern is that the FDA is less predictable. Without a permanent commissioner driving a consistent philosophy, individual review divisions are making decisions based on their own assessment of the evidence and the appropriate level of scrutiny. Some divisions are leaning constructive. Others are leaning cautious. The practical advice for companies: prepare for both outcomes. Build the adcomm into the timeline. Hope for the Replimune result. Plan for the Capricor one.
3. The Convenience Frontier Is Reshaping Competition Across Therapeutic Areas
Zumilokibart at two to four injections per year versus Dupixent’s 26 in eczema. Lumvoa with a shorter infusion course versus Tepezza in thyroid eye disease. Foundayo with no food restrictions versus oral semaglutide requiring fasting in diabetes. The pattern of 2026 is that when two drugs offer comparable efficacy, the one that is easier to take wins the next generation of market share. Convenience is no longer a nice to have. It is a competitive differentiator that determines which drugs physicians prescribe and which drugs patients stay on.
4. Tomorrow Is the Starting Gun for the Biggest New Patient Market in GLP 1 History
Sixty five million Medicare beneficiaries. Both Lilly and Novo products covered. $50 per month copay. The Bridge program adds a patient population that has been almost entirely excluded from the GLP 1 revolution due to cost barriers. The enrollment data starting tomorrow will answer the question that the entire market is asking: how deep is the pent up demand for obesity and diabetes treatment in the Medicare population when price is no longer the barrier?
Frequently Asked Questions
What is the Ipsen/Kartos deal?
Ipsen is acquiring Kartos Therapeutics for $450 million upfront and up to $1.75 billion total. The asset is navtemadlin, a Phase 3 MDM2 inhibitor designed to improve outcomes for myelofibrosis patients on Jakafi. This is mid cap pharma building around a core franchise.
What is the Zymeworks/Theravance deal?
Zymeworks is acquiring Theravance Biopharma for close to $1 billion. The deal adds a lung disease drug and royalty streams. Notable because Zymeworks is transitioning from a platform licensor to a diversified, revenue generating company.
What happened with Capricor?
The FDA set a surprise advisory committee meeting for deramiocel in Duchenne cardiomyopathy. The drug was rejected last July. CEO Linda Marbán said the FDA had not communicated any concerns with the resubmission. The August 22 PDUFA date is now uncertain.
What is Lumvoa?
Viridian’s veligrotug, an anti IGF 1R antibody approved for thyroid eye disease. Competes with Amgen’s Tepezza with a shorter infusion course. Shares rose 10% on the approval.
What is the Enhertu EU approval?
Tumor agnostic approval for HER2 positive (IHC 3+) solid tumors in Europe. Enhertu can now be used based on biomarker status regardless of cancer type. Extends the AstraZeneca/Daiichi Sankyo ADC franchise.
When does the Medicare Bridge launch?
Tomorrow, July 1. Foundayo, Zepbound, oral Wegovy, and injectable Wegovy all covered at $50 per month copay for Medicare Part D beneficiaries.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
M&A Broadens. We analyze why mid cap and biotech buyers entering the market signals a structural shift rather than a peak, compare the Ipsen “shots around a franchise” strategy to big pharma mega deals, and assess what the buyer broadening means for the second half deal calendar.
The Uneven FDA. We assess how the Capricor adcomm complicates the regulatory shift narrative from Replimune, UniQure, and REGENXBIO, identify which review divisions appear to be leaning constructive versus cautious, and evaluate the implications for every rare disease filing in the queue.
TED Market. We analyze what Viridian’s Lumvoa approval means for Amgen’s Tepezza franchise, model the market share impact of a shorter infusion course, and assess how the convenience competition parallels the dynamics in eczema and GLP 1.
Plus: Enhertu tumor agnostic franchise expansion, myelofibrosis competitive landscape (navtemadlin versus Ajax JAK2), Medicare Bridge launch day guide, and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
